Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN
FORT Study to assess efficacy and safety of novel replacement therapy
View HTML
Toggle Summary Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued Patents in the United States and Europe
SAN DIEGO , June 01, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have each issued a patent covering the Company's product candidate sparsentan, which is advancing to Phase 3
View HTML
Toggle Summary Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses
Subgroup analysis from Phase 2 DUET study of sparsentan in FSGS to be presented at ERA-EDTA PKAN-ADL scale in Phase 3 FORT study of RE-024 in PKAN to be highlighted at MDS SAN DIEGO , May 25, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced upcoming presentations related to
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2017 Global Healthcare Conference
SAN DIEGO , May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET .
View HTML
Toggle Summary Retrophin Reports First Quarter 2017 Financial Results
Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO , May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin to Report First Quarter 2017 Financial Results
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Appoints Ron Squarer to Board of Directors
SAN DIEGO , April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company's Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma Inc., a biopharmaceutical company focused
View HTML
Toggle Summary John A. Orwin Joins Retrophin Board of Directors
SAN DIEGO , March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company's Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc.
View HTML
Toggle Summary Retrophin to Present at the Barclays Global Healthcare Conference
SAN DIEGO , March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET .
View HTML
Toggle Summary Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results
Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million Conference call today at 5:00 p.m.
View HTML